STOCK TITAN

60 Degrees Pharmaceuticals (SXTP) DEF 14A Filings

SXTP NASDAQ

Here are the DEF 14A proxy statements from 60 Degrees Pharmaceuticals, Inc. (SXTP) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow SXTP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SXTP filings page.

Rhea-AI Summary

60 Degrees Pharmaceuticals is asking stockholders to approve several major governance items at its 2026 virtual annual meeting on August 5, 2026. Holders of 2,659,288 shares outstanding as of July 2, 2026 can vote by telephone or mail.

Stockholders will vote on electing five directors, including proposed new director and audit chair Eric Francois, expanding the 2022 Equity Incentive Plan by 800,000 shares to a total reserve of 962,889 shares, and authorizing a reverse stock split at a ratio between 1:5 and 1:10 at the Board’s discretion. Other proposals include ratifying RBSM LLP as auditor, approving a management success fee tied to a change of control or strategic transaction, and allowing adjournment to solicit additional proxies.